Cellomics and GE Healthcare Collaborate To Provide Faster and More Effective Cellular Screening Solutions.PITTSBURGH -- Software Development and Commercialization Agreement Offers Informatics Same as information technology and information systems. The term is more widely used in Europe. Solution for High Content Cellular Analysis Cellomics, Inc. and GE Healthcare GE Healthcare is a $18 billion (USD) unit of General Electric (GE). It employs more than 46,000 people worldwide and is headquartered in Chalfont St. Giles, Buckinghamshire, United Kingdom. GE Healthcare is the first GE business segment headquartered outside the United States. (a combination of the former Amersham and GE Medical Systems) today announced a software development and commercialization agreement aimed at facilitating faster and more efficient drug development. Under the terms of the agreement, the two companies will collaborate to develop and market an interface that permits High Content Screening (HCS HCS - Heterogeneous Computer System A distributed system project. ) analysis utilizing both GE Healthcare's sub-cellular imaging instruments and Cellomics' high content informatics (HCi(TM)) platform. Under the agreement, Cellomics will develop and sell software that allows data and images generated by GE Healthcare's IN Cell Analyzer 3000 and IN Cell Analyzer 1000 sub-cellular imaging systems to be extracted and interrogated by Cellomics(R) Store and vHCS(TM) Discovery ToolBox See toolkit and toolbar. , key components of Cellomics' HCi platform. When used with the IN Cell Analyzer 3000 and IN Cell Analyzer 1000 systems, the software will enable researchers to easily store, mine and interpret data, and so make faster and more informed decisions in their drug development process. "This collaboration with Cellomics supports GE Healthcare's strategy of helping customers improve efficiencies in gathering, analyzing, and understanding complex drug development information," said Michael Evans Michael (or Mike) Evans may refer to: In religion:
"Our customers have found high value by utilizing our proprietary HCi solutions for the management and analysis of their HCS data," commented Daniel J. Calvo, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cellomics. "These tools are vital to the success of HCS programs in both drug discovery and basic life science research. We are pleased that we will be able to combine our informatics solution expertise with GE Healthcare's cellular analysis products to drive towards the ultimate goal of cutting drug development time." About Cellomics Cellomics, Inc. is automating drug discovery through a unique, cell-based assay platform that addresses the needs of Drug Discovery and Systems Biology Systems biology, a field of study in the biosciences, focuses on the systematic study of complex interactions in biological systems. Particularly from 2000 onwards, the term is used widely in the biosciences, and in a variety of contexts. groups by offering complete systems for High Content Screening (HCS). The platform includes HCS instrumentation (both fixed end-point and kinetic kinetic /ki·net·ic/ (ki-net´ik) pertaining to or producing motion. ki·net·ic adj. Of, relating to, or produced by motion. kinetic pertaining to or producing motion. systems), informatics, cellular image analysis software (BioApplications), fluorescent reagents, kits, cell lines, and multiparametric assays. When applied to early drug discovery, this platform is proving to reduce the 'idea-to-discovery' cycle time in drug discovery, while increasing the probability of the therapeutic success of leads as well as enhancing throughput in systems biology and basic research. Cellomics' proprietary platforms, including the ArrayScan(R) and KineticScan(R) HCS Readers, along with the HCi software platform and BioApplications, are in use at multiple sites within all of the top fifteen pharmaceutical companies, as well as leading pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. and academic centers globally. For more information about Cellomics, visit our website at www.cellomics.com. About GE Healthcare GE Healthcare provides transformational medical technologies that are shaping a new age of patient care. GE Healthcare's expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery and biopharmaceuticals is dedicated to detecting disease earlier and tailoring treatment for individual patients. GE Healthcare offers a broad range of services to improve productivity in healthcare and enable healthcare providers to better diagnose, treat and manage patients with conditions such as cancer, Alzheimer's and cardiovascular diseases Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . GE Healthcare is a $14 billion unit of General Electric Company (NYSE NYSE See: New York Stock Exchange : GE) that is headquartered in the United Kingdom. Worldwide, GE Healthcare employs more than 42,500 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion